Skip to main content
. Author manuscript; available in PMC: 2013 Dec 7.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2012 Jan 19;83(1):10.1016/j.ijrobp.2011.06.1990. doi: 10.1016/j.ijrobp.2011.06.1990

Figure 4.

Figure 4

EQD2 for HNC cell lines treated with 2.0 Gy x 35 (top) and 5.0 Gy x 6 (bottom), with and without concurrent cisplatin. * denotes addition of cetuximab. Error bars indicate 95% confidence intervals. <> denotes a significant (p<0.05) increase in EQD2 with the addition of drug using paired Student’s t-test.